Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
16 Jan 2024
16 Jan 2024
Historique:
received:
13
12
2023
accepted:
21
12
2023
medline:
16
1
2024
pubmed:
16
1
2024
entrez:
16
1
2024
Statut:
aheadofprint
Résumé
Intraoperative carcinoid crisis is typically sudden onset of profound hypotension during operations on patients with neuroendocrine tumors. The crisis was thought to be due to massive release of hormones, and perioperative octreotide was recommended as a prophylaxis against the crisis and as first-line treatment. Recent studies show that octreotide does not prevent the crisis and that no massive release of hormones occurs. Therefore, the authors hypothesized that octreotide is not effective for treating the crisis. A prospective carcinoid anesthesia database was analyzed for occurrences of crisis. Outcomes were compared between protocols when first-line therapy was bolus octreotide and when it was vasopressors without octreotide. Significance was determined by Student's t test, the Mann-Whitney U test, and Fisher's exact test. Among operations performed with octreotide as first-line treatment (n = 150), crisis occurred for 45 (30 %) patients, the median crisis duration was 6 min, 12 (27 %) patients had crises longer than 10 min, 42 patients (93 %) required subsequent vasopressor administration to resolve the crisis, and 3 (2 %) operations were aborted. Among operations performed with vasopressors as the first-line treatment (n = 195), crisis occurred for 49 (25 %) patients (p = 0.31), the median crisis duration was 3 min (p < 0.001), and no crisis lasted longer than 10 min (p = 0.001). Patients treated with vasopressors were less likely to have multiple crises and had a shorter total time in crisis, a shorter anesthesia time, and no aborted operations (p < 0.05 for all). First-line octreotide was ineffective treatment for carcinoid crisis, with patients requiring vasopressors to resolve the crisis, and many crises lasting longer than 10 min. First-line vasopressor treatment resulted in significantly shorter crisis durations, fewer crises and aborted operations, and shorter anesthesia times. Vasopressors should be used as first-line treatment for intraoperative crisis, and treatment guidelines should be changed.
Sections du résumé
BACKGROUND
BACKGROUND
Intraoperative carcinoid crisis is typically sudden onset of profound hypotension during operations on patients with neuroendocrine tumors. The crisis was thought to be due to massive release of hormones, and perioperative octreotide was recommended as a prophylaxis against the crisis and as first-line treatment. Recent studies show that octreotide does not prevent the crisis and that no massive release of hormones occurs. Therefore, the authors hypothesized that octreotide is not effective for treating the crisis.
METHODS
METHODS
A prospective carcinoid anesthesia database was analyzed for occurrences of crisis. Outcomes were compared between protocols when first-line therapy was bolus octreotide and when it was vasopressors without octreotide. Significance was determined by Student's t test, the Mann-Whitney U test, and Fisher's exact test.
RESULTS
RESULTS
Among operations performed with octreotide as first-line treatment (n = 150), crisis occurred for 45 (30 %) patients, the median crisis duration was 6 min, 12 (27 %) patients had crises longer than 10 min, 42 patients (93 %) required subsequent vasopressor administration to resolve the crisis, and 3 (2 %) operations were aborted. Among operations performed with vasopressors as the first-line treatment (n = 195), crisis occurred for 49 (25 %) patients (p = 0.31), the median crisis duration was 3 min (p < 0.001), and no crisis lasted longer than 10 min (p = 0.001). Patients treated with vasopressors were less likely to have multiple crises and had a shorter total time in crisis, a shorter anesthesia time, and no aborted operations (p < 0.05 for all).
CONCLUSIONS
CONCLUSIONS
First-line octreotide was ineffective treatment for carcinoid crisis, with patients requiring vasopressors to resolve the crisis, and many crises lasting longer than 10 min. First-line vasopressor treatment resulted in significantly shorter crisis durations, fewer crises and aborted operations, and shorter anesthesia times. Vasopressors should be used as first-line treatment for intraoperative crisis, and treatment guidelines should be changed.
Identifiants
pubmed: 38227166
doi: 10.1245/s10434-023-14876-4
pii: 10.1245/s10434-023-14876-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Society of Surgical Oncology.
Références
Magabe PC, Bloom AL. Sudden death from carcinoid crisis during image-guided biopsy of a lung mass. J Vasc Interv Radiol. 2014;25:484–7.
doi: 10.1016/j.jvir.2013.10.054
pubmed: 24581473
Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39:753–66.
doi: 10.1097/MPA.0b013e3181ebb2a5
pubmed: 20664473
Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–85.
doi: 10.1159/000443167
pubmed: 26731013
Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6–32.
doi: 10.1136/gutjnl-2011-300831
pubmed: 22052063
Kvols LK, Martin JK, Marsh HM, Moertel CG. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med. 1985;313:1229–30.
doi: 10.1056/NEJM198511073131916
pubmed: 2865675
Kinney MA, Warner ME, Nagorney DM, et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth. 2001;87:447–52.
doi: 10.1093/bja/87.3.447
pubmed: 11517130
Condron ME, Jameson NE, Limbach KE, et al. A prospective study of the pathophysiology of carcinoid crisis. Surgery. 2019;165:158–65.
doi: 10.1016/j.surg.2018.04.093
pubmed: 30415870
Condron ME, Pommier SJ, Pommier RF. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery. 2016;159:358–65.
doi: 10.1016/j.surg.2015.05.036
pubmed: 26603846
Kwon DH, Paciorek A, Mulvey CK, et al. Periprocedural management of patients undergoing liver resection or embolotherapy for neuroendocrine tumor metastases. Pancreas. 2019;48:496–503.
doi: 10.1097/MPA.0000000000001271
pubmed: 30946246
Massimino K, Harrskog O, Pommier S, Pommier R. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients. J Surg Oncol. 2013;107:842–6.
doi: 10.1002/jso.23323
pubmed: 23592524
Guo LJ, Tang CW. Somatostatin analogues do not prevent carcinoid crisis. Asian Pac J Cancer Prev. 2014;15:6679–83.
doi: 10.7314/APJCP.2014.15.16.6679
pubmed: 25169508
Xu A, Suz P, Reljic T, et al. Perioperative carcinoid crisis: a systematic review and meta-analysis. Cancers Basel. 2022;14:2966.
doi: 10.3390/cancers14122966
pubmed: 35740631
pmcid: 9221110
Wonn SM, Ratzlaff AN, Pommier SJ, McCully BH, Pommier RF. A prospective study of carcinoid crisis with no perioperative octreotide. Surgery. 2022;171:88–93.
doi: 10.1016/j.surg.2021.03.063
pubmed: 34226047
Limbach KE, Condron ME, Bingham AE, Pommier SJ, Pommier RF. Beta-adrenergic agonist administration is not associated with secondary carcinoid crisis in patients with carcinoid tumor. Am J Surg. 2019;217:932–6.
doi: 10.1016/j.amjsurg.2018.12.070
pubmed: 30635207
Hoeldtke RD, Davis KM, Joseph J, Gonzales R, Panidis IP, Friedman AC. Hemodynamic effects of octreotide in patients with autonomic neuropathy. Circulation. 1991;84:168–76.
doi: 10.1161/01.CIR.84.1.168
pubmed: 2060092
Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology. 2001;120:975–83.
doi: 10.1053/gast.2001.22529
pubmed: 11231951